Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: A potential risk factor determinant for type 2 diabetic retinopathy

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 7480-7491

  Ng, Zhi Xiang ^a   Chua, Kek Heng ^a   Iqbal, Tajunisah ^a   Kuppusamy, Umah Rani ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Advanced oxidation protein product; Antioxidant enzymes; Diabetic retinopathy; Oxidative stress; Pentosidine; Risk factor; Soluble receptor for advanced glycation end product

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED OXIDATION PROTEIN PRODUCT; CHOLESTEROL; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTOSIDINE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; ARGININE; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCT PENTOSIDINE RATIO; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; MIDDLE AGED;

ADULT; ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; ANTIGENS, NEOPLASM; ARGININE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; LYSINE; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; RISK FACTORS; SUPEROXIDE DISMUTASE;

EID: 84875982918     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14047480     Document Type: Article

References (32)

1. Ooyub, S.; Ismail, F.; Daud, N.A. Diabetes program in Malaysia-current and future. NCD Malays. 2004, 3, 6-12.
2. Zanariah, H.; Chandran, L.R.; wan Mohamad, W.B.; wan Nazaimoon, W.M.; Letchuman, G.R.; Jamaiyah, H.; Fatanah, I.; Nurain, M.N.; Helen Tee, G.H.; Mohd Rodi, I. DWP1-3 Prevalence of diabetes mellitus in Malaysia in 2006-Results of the 3rd National Health and Morbidity Survey (NHMS III). Diabetes Res. Clin. Pract. 2008, 79, S21.
3. Uthra, S.; Raman, R.; Mukesh, B.N.; Rajkumar, S.A.; Padmaja, K.R.; Paul, P.G.; Lakshmipathy, P.; Gnanamoorthy, P.; Sharma, T.; McCarty, C.A.; et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet 2008, 29, 11-15.
4. Goh, P.P. Status of diabetic retinopathy among diabetics registered to the Diabetic Eye Registry, National Eye Database, 2007. Med. J. Malays. 2008, 63, 24-28.
5. Betteridge, D.J. What is oxidative stress? Metabolism 2000, 49, 3-8.
6. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44-84.
7. Costagliola, C. Oxidative state of glutathione in red blood cells and plasma of diabetic patients: In vivo and in vitro study. Clin. Physiol. Biochem. 1990, 8, 204-210.
8. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82, 47-95.
9. Kankova, K.; Marova, I.; Zahejsky, J.; Muzik, J.; Stejskalova, A.; Znojil, V.; Vacha, J. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 2001, 50, 1152-1160.
10. Hudson, B.I.; Hofmann, M.; Bucciarelli, L.; Wendt, T.; Moser, B.; Lu, Y.; Qu, W.; Stern, D.; D'Agati, V.; Yan, S.D.; et al. Glycation and diabetes: The RAGE connection. Curr. Sci. 2002, 83, 1515-1521.
11. Kalousova, M.; Jachymova, M.; Mestek, O.; Hodkova, M.; Kazderova, M.; Tesar, V.; Zima, T. Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2007, 22, 2020-2026.
12. Grossin, N.; Wautier, M.P.; Meas, T.; Guillausseau, P.J.; Massin, P.; Wautier, J.L. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008, 34, 392-395.
13. Nazratun, N.; Mahmood, A.A.; Kuppusamy, U.R.; Ahmad, T.S.; Tan, S.Y. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc. Med. 2006, 11, 245-250.
14. Challier, M.; Jacqueminet, S.; Benabdesselam, O.; Grimaldi, A.; Beaudeux, J.L. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin. Chem. 2005, 51, 1749-1750.
15. Al-Mesallamy, H.O.; Hammad, L.N.; El-Mamoun, T.A.; Khalil, B.M. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J. Diabetes Complicat. 2010, 25, 168-174.
16. Nakamura, K.; Yamagishi, S.I.; Matsui, T.; Adachi, H.; Takeuchi, M.; Imaizumi, T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin. Exp. Med. 2007, 7, 188-190.
17. Forbes, J.M.; Thorpe, S.R.; Thallas-Bonke, V.; Pete, J.; Thomas, M.C.; Deemer, E.R.; Bassal, S.; El-Osta, A.; Long, D.M.; Panagiotopoulos, S.; et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2005, 16, 2363-2372.
18. Salman, A.G.; Mansour, D.E.; Swelem, A.H.; Al-Zawahary, W.M.; Radwan, A.A. Pentosidine-A new biochemical marker in diabetic retinopathy. Ophthalmic Res. 2009, 42, 96-98.
19. Stitt, A.W. AGEs and diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2010, 51, 4867-4874.
20. Mates, J.M.; Perez-Gomez, C.; Nunez de Castro, I. Antioxidant enzymes and human diseases. Clin. Biochem. 1999, 32, 595-603.
21. Ramakrishna, V.; Jailkhani, R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008, 45, 41-46.
22. Kalousova, M.; Sulkova, S.; Fialova, L.; Soukupova, J.; Malbohan, I.M.; Spacek, P.; Braun, M.; Mikulikova, L.; Fortova, M.; Horejsi, M.; et al. Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2003, 18, 2577-2581.
23. Witko-Sarsat, V.; Friedlander, M.; Nguyen Khoa, T.; Capeillere-Blandin, C.; Nguyen, A.T.; Canteloup, S.; Dayer, J.M.; Jungers, P.; Drueke, T.; Descamps-Latscha, B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 1998, 161, 2524-2532.
24. Hammes, H.P.; Brownlee, M.; Lin, J.; Schleicher, E.; Bretzel, R.G. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 1999, 42, 603-607.
25. Boehm, B.O.; Schilling, S.; Rosinger, S.; Lang, G.E.; Lang, G.K.; Kientsch-Engel, R.; Stahl, P. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004, 47, 1376-1379.
26. Kalousova, M.; Zima, T.; Tesar, V.; Dusilova-Sulkova, S.; Skrha, J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res. 2005, 579, 37-46.
27. Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 1981, 21, 1-226.
28. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98, 823-833.
29. Grading diabetic retinopathy from stereoscopic color fundus photographs-An extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98, 786-806.
30. Boyum, A. Separation of leukocytes from blood and bone marrow. Introduction. Scand. J. Clin. Lab. Invest. Suppl. 1968, 97, 7.
31. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
32. Witko-Sarsat, V.; Friedlander, M.; Capeillere-Blandin, C.; Nguyen-Khoa, T.; Nguyen, A.T.; Zingraff, J.; Jungers, P.; Descamps-Latscha, B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49, 1304-1313.